OrganiGram (OGI) investor relations material

Strategic direction

• Four priorities: strengthen the Canadian base, expand internationally, improve manufacturing and innovation, and allocate capital with disciplined ROI focus.

• Long-term aim: turn market positions and capabilities into profitable growth, consistent cash generation, and shareholder value.

• Compared with the prior market-share-led approach, profitability now takes priority in Canada; brand and SKU reductions will be gradual while preserving revenue and building brand strength.

• Over four to five years, management could reduce the brand and SKU count to half of current levels; SHRED, BOXHOT, and Big Bag O' Buds are key brands, alongside some regional brands.

• Capital decisions will favor fewer opportunities with clear returns, assessed for strategic fit, bottom-line contribution, cash generation, liquidity, and ROI.

Canadian business, operations, and innovation

• SKU count fell ~10% over the past year; selected low-margin wholesale white-label segments were exited, supporting margin improvement.

• Moncton cultivation yield increased by 30,000 kg; average potency exceeded 30% in Q3. Faster room turnaround added capacity for >3,300 kg annually with virtually no capex.

• Shifting 95 grow rooms to alternating day/night schedules reduced electricity costs by ~CAD 85,000 monthly while maintaining production performance.

• Automation projects are planned over the next few months to reduce COGS; Q2-to-Q3 complaints fell 28% for vapes and 29% for pre-rolls.

• Canada-only gross margin target is mid-40s, supported by cultivation efficiency, SKU rationalization, and prioritizing more profitable products.

International expansion

• Sanity transformed the geographic mix: international revenue rose from ~10% in FY2025 to ~35% after consolidation in Q3; its segment reported EUR 25.5m two quarters after Q4 2025 revenue of EUR 19m.

• Sanity generated EUR 9m revenue in 2023, EUR 19m in 2024, and EUR 60m in 2025; its German medical brand avaay was estimated to lead by market share.

• Germany is the current scale market; management expects its medical market to double by 2028, with Sanity at an annualized revenue run rate above EUR 100m.

• By FY2027 year-end, international and Canadian revenue could be much more balanced; longer term, the goal is a diversified business with predominantly international, higher-margin revenue.

• Expansion is underway in Switzerland and the U.K.; Czech Republic, Poland, Slovenia, and Ukraine are in development, with all three expected to generate revenue within 18 months.